Get started
Work

Safety and pharmacokinetics (PK) of cabazitaxel (C) in patients (pts) with hepatic impairment (HI).

Year: 2015
Type: conference-abstract
DOI: 10.1200/jco.2015.33.15_suppl.2538
Authors: John Sarantopoulos, Alain C. Mita, Aiwu Ruth He, James Lloyd Wade, Chung-Tsen Hsueh, John Charles Morris, Albert C. Lockhart, David Quinn, Jimmy J. Hwang, James Walter Mier, Wenping Zhang, Claudine Wack, Jian Yin, Pierre-François Clot, Olivier Rixe
Institutions: The University of Texas at San Antonio Health Science Center, Georgetown University, Georgetown Lombardi Comprehensive Cancer Center, Loma Linda University, University of Cincinnati, University of Cincinnati Medical Center, Washington University in St. Louis, Alvin J. Siteman Cancer Center, USC Norris Comprehensive Cancer Center, Beth Israel Deaconess Medical Center, Harvard University, Dana-Farber/Harvard Cancer Center, Sanofi (United States), Sanofi (France), UNM Comprehensive Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: closed
OpenAlex ID: W2602152634
Cites:
Cited by:
Related to: 10